Small molecule · developed by Lakefront Biotherapeutics NV
Cadefrecitinib (GLPG3667) is an investigational agent studied in healthy participants and in dermatomyositis, given orally, as a capsule, and as an intravenous infusion of a radiolabeled microdose.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05695950 | Phase 2 | Dermatomyositis | Completed | LKFT |
| NCT05335447 | Phase 1 | Healthy | Completed | LKFT |
| NCT04097938 | Phase 1 | Healthy | Completed | LKFT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
DermatomyositisHealthy
Updated Nov 15, 2026. Something wrong or missing? Report it on the LKFT page.
See LKFT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LKFT catalysts and pipeline →